-
Mashup Score: 1
Initiation of randomized, double-blind, placebo-controlled Phase II trial of merimepodib, an orally administered broad-spectrum anti-viral, in combination with intravenous remdesivir in patients with advanced COVID-19 (hospitalized and…
Source: BioSig Technologies, Inc.Categories: Hem/Oncs, Latest HeadlinesTweet
Very excited to be the institutional PI on this #COVID19 study looking at a novel antiviral in combination with #remdesivir https://t.co/WOQ68Os7yy #beyondmelanoma @BioSig_Tech #stillascientistatheart